Payment overview · 2025
General Payments
$289.19
10 reported records · 2 companies
Healthcare provider profile · identity verified
Jeffrey C Jones, M.D.
Allopathic & Osteopathic Physicians|Family Medicine|Sleep Medicine · DUNCAN, OK · NPI 1811997992
Verified facts
What the public records show
CMS Open Payments records show Jeffrey C Jones, M.D. received $289.19 in general payments during 2025 across 10 reported records.
HARMONY BIOSCIENCES LLC accounted for 56.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Xywav.
JAZZ PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XYWAV as an associated drug or biological on 19511 records involving 5343 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xywav by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $163.00 | 56.4% | 5 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $126.19 | 43.6% | 5 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $234.20 | 9 |
| Education | $54.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $126.19 | 5 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $108.01 | 4 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| XYWAV xywav |
2025 | Xywav | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| JAZZ PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | XYWAV open payments reported associated product |
CMS Open Payments — General Payments 19511 supporting records · 5343 recipient NPIs · example record 1234297700 |
Xywav · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 459 | 114 |
| Lisinopril | Lisinopril | 319 | 85 |
| Omeprazole | Omeprazole | 297 | 74 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 254 | 57 |
| Losartan Potassium | Losartan Potassium | 237 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 232 | 59 |
| Atorvastatin Calcium | Atorvastatin Calcium | 232 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 227 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 192 | 48 |
| Gabapentin | Gabapentin | 183 | 53 |
| Furosemide | Furosemide | 180 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 166 | 41 |
| Trazodone Hcl | Trazodone Hcl | 163 | 49 |
| Ropinirole Hcl | Ropinirole Hcl | 146 | 44 |
| Metformin Hcl Er | Metformin Hcl | 140 | 39 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 137 | 34 |
| Allopurinol | Allopurinol | 118 | 26 |
| Meloxicam | Meloxicam | 117 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 113 | 42 |
| Potassium Chloride | Potassium Chloride | 110 | 35 |
| Alprazolam | Alprazolam | 109 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 107 | 32 |
| Clonazepam | Clonazepam | 100 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 99 | 30 |
| Carvedilol | Carvedilol | 98 | 27 |
| Ozempic | Semaglutide | 97 | 12 |
| Fluconazole | Fluconazole | 95 | 29 |
| Sertraline Hcl | Sertraline Hcl | 94 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 92 | 25 |
| Simvastatin | Simvastatin | 89 | 27 |
| Montelukast Sodium | Montelukast Sodium | 87 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 79 | 57 |
| Lorazepam | Lorazepam | 76 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 21 |
| Ondansetron Odt | Ondansetron | 75 | 23 |
| Estradiol | Estradiol | 72 | 26 |
| Dicyclomine Hcl | Dicyclomine Hcl | 65 | 18 |
| Atenolol | Atenolol | 64 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 63 | 19 |
| Pregabalin | Pregabalin | 63 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 60 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 15 |
| Buspirone Hcl | Buspirone Hcl | 53 | 16 |
| Celecoxib | Celecoxib | 53 | 19 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 53 | suppressed |
| Bupropion Xl | Bupropion Hcl | 52 | suppressed |
| Trulicity | Dulaglutide | 51 | suppressed |
| Xarelto | Rivaroxaban | 50 | suppressed |
| Glimepiride | Glimepiride | 49 | 12 |
| Farxiga | Dapagliflozin Propanediol | 48 | 13 |
| Jardiance | Empagliflozin | 48 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | 13 |
| Clonidine Hcl | Clonidine Hcl | 42 | 21 |
| Oxybutynin Chloride | Oxybutynin Chloride | 42 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 42 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | 13 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 38 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | 11 |
| Spironolactone | Spironolactone | 37 | suppressed |
| Topiramate | Topiramate | 36 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Famotidine | Famotidine | 34 | 14 |
| Alendronate Sodium | Alendronate Sodium | 33 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 33 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Methocarbamol | Methocarbamol | 33 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Telmisartan | Telmisartan | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 18 |
| Cephalexin | Cephalexin | 32 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 24 |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 32 | suppressed |
| Prednisone | Prednisone | 32 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Sucralfate | Sucralfate | 31 | suppressed |
| Eliquis | Apixaban | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Naproxen | Naproxen | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | 12 |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 26 | suppressed |
| Ibuprofen | Ibuprofen | 26 | 11 |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 26 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 24 | suppressed |
| Primidone | Primidone | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 19 |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Minoxidil | Minoxidil | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Constulose | Lactulose | 15 | suppressed |
| Metformin Hcl | Metformin Hcl | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Pentoxifylline | Pentoxifylline | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 12 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Temazepam | Temazepam | 12 | 11 |
| Xywav | Sodium,calcium,mag,pot Oxybate | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Dexamethasone | Dexamethasone | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $289.19 · 10 records | HARMONY BIOSCIENCES LLC | WAKIX, XYWAV | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Xywav play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with JAZZ PHARMACEUTICALS INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error